DDrare: Database of Drug Development for Rare Diseases

Searched query = "Microscopic polyangiitis", "MPA"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 5009111000001105; Alemtuzumab; Avacopan; Azathioprine; BELIMUMAB; Belimumab; Belimumab 10 mg/kg; Benlysta; Benlysta 400 mg powder for concentrate for solution for infusion; Benlysta 400mg polvere per concentrato per soluzione per infusione; Blisibimod; CCX168; CELLCEPT; CYCLOPHOSPHAMIDE; CellCept (mycophenolate mofetil); Cellcept; Chimeric monoclonal antibody, IgG4 subtype; Corticosteroid; Corticosteroid and azathioprine; Cyclophosphamide; Cyclophosphamide, Azathioprine,prednisone,methylprednisolone; DELTACORTENE; ENDOXAN BAXTER; Endoxan; Freeze-Dried Sulfonated Human Normal Immunoglobulin (GGS); GALEN® tablet; Glucocorticoid (GC); Glucocorticoids; Glucocorticoids (GC); Glucocorticoids - Reduced Dose; Glucocorticoids - Standard Dose; Glucocorticoids [Reduced Dose]; Glucocorticoids [Standard Dose]; Human normal immunoglobulin; Hydroxychloroquine; IFX-1; Infliximab; Intravenous immunoglobulins (human immunoglobulins G); Intravenous methyl prednisolone; MabThera; MabThera®; MabThera® 100MG; MabThera® 500MG; Methotrexate; Methyl prednisolone; Methylprednisolone; Methylprednisolone (or other glucocorticoid); Mycophenolate; Mycophenolate Mofetil; Mycophenolate mofetil; Mycophenolate mofetil,methotrexate; Mycophenolic acid; Naltrexone; Naltrexone Hydrochloride; Other: No Plasma Exchange; PREDNISONE; Pednisone; Placebo (physiological saline); Plaquenil - Hydroxychloroquine 200mg Film coated tablets; PredniSONE Tablets, USP; Prednisolone; Prednison acis® 20 mg; Prednison acis® 5 mg; Prednisone; Prednisone (and methylprednisolone); Prednisone, methylprednisolone,cyclophosphamides; Procedure: Plasma Exchange; Procedure: Plasma exchange; RITUXIMAB; RIXATHON 500mg; RO0452294/V01; RO0452294/V02; Remission induction therapy; Rituximab; Rituximab (Arm A); Rituximab (Arm B); Ro106-1443; Sendoxan; Tocilizumab; Vitamin D

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04316494 (ClinicalTrials.gov)	April 2020	25/2/2020	Hydroxychloroquine in ANCA Vasculitis Evaluation	Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial	ANCA Associated Vasculitis;Microscopic Polyangiitis;Churg-Strauss Syndrome;Wegener Granulomatosis	Drug: Hydroxychloroquine;Drug: Placebo	Guy's and St Thomas' NHS Foundation Trust	Medical Research Council	Not yet recruiting	18 Years	N/A	All	76	Phase 4	NULL
2	EUCTR2018-001268-40-GB (EUCTR)	23/01/2020	13/09/2019	Hydroxychloroquine in ANCA vasculitis	Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial - HAVEN	The term ANCA-associated vasculitis (AAV) describes a subset of primary small vessel vasculitides characterized by the presence of anti-neutrophil cytoplasmic antibodies (ANCA): Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and Eosinophilic Granulomatosis with Polyangiitis (EGPA). AAV are serious multisystem autoimmune disorders that can affect any organ in the body and commonly involve the ear-nose-throat, lungs, kidneys, eyes and joints MedDRA version: 20.0;Level: SOC;Classification code 10021428;Term: Immune system disorders;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]	Trade Name: Plaquenil - Hydroxychloroquine 200mg Film coated tablets	Guy's and St. Thomas' NHS Foundation Trust	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	76	Phase 4	United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04316494
(ClinicalTrials.gov)

April 2020

25/2/2020

Hydroxychloroquine in ANCA Vasculitis Evaluation

Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial

ANCA Associated Vasculitis;Microscopic Polyangiitis;Churg-Strauss Syndrome;Wegener Granulomatosis

Drug: Hydroxychloroquine;Drug: Placebo

Guy's and St Thomas' NHS Foundation Trust

Medical Research Council

Not yet recruiting

18 Years

N/A

All

Phase 4

NULL

EUCTR2018-001268-40-GB
(EUCTR)

23/01/2020

13/09/2019

Hydroxychloroquine in ANCA vasculitis

Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial - HAVEN

The term ANCA-associated vasculitis (AAV) describes a subset of primary small vessel vasculitides characterized by the presence of anti-neutrophil cytoplasmic antibodies (ANCA): Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and Eosinophilic Granulomatosis with Polyangiitis (EGPA). AAV are serious multisystem autoimmune disorders that can affect any organ in the body and commonly involve the ear-nose-throat, lungs, kidneys, eyes and joints
MedDRA version: 20.0;Level: SOC;Classification code 10021428;Term: Immune system disorders;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]

Trade Name: Plaquenil - Hydroxychloroquine 200mg Film coated tablets

Guy's and St. Thomas' NHS Foundation Trust

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 4

United Kingdom